If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> <br /> Contents<br /> + EDITORIAL BOARD 4<br /> + WELCOME 7<br /> + FOREWORD 9<br /> + CONGRESS REVIEW<br /> Review of The European League Against Rheumatism (EULAR) Congress 10<br /> 2019, held in Madrid, Spain, 12th–15th June, 2019.<br /> + CONGRESS INTERVIEWS<br /> Meet the Editorial Board 25<br /> Meet the Organisers 29<br /> + SYMPOSIUM REVIEWS<br /> Optimising Patient Management in Rheumatoid Arthritis: Can We Live Up 33<br /> to Patient Expectat<a title="EMJ Rheumatology 6.1 2019 page 1" href="http://viewer.zmags.com/publication/ad75fc2f?page=1"> </a> <a title="EMJ Rheumatology 6.1 2019 page 2" href="http://viewer.zmags.com/publication/ad75fc2f?page=2"> Contents + EDITORIAL BOARD </a> <a title="EMJ Rheumatology 6.1 2019 page 3" href="http://viewer.zmags.com/publication/ad75fc2f?page=3"> “A wide range of novel topics related to clinical</a> <a title="EMJ Rheumatology 6.1 2019 page 4" href="http://viewer.zmags.com/publication/ad75fc2f?page=4"> Editorial Board Editor-in-Chief Dr Ian C. Chikanz</a> <a title="EMJ Rheumatology 6.1 2019 page 5" href="http://viewer.zmags.com/publication/ad75fc2f?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Rheumatology 6.1 2019 page 6" href="http://viewer.zmags.com/publication/ad75fc2f?page=6"> EMJ Rheumatol. Chief Executive Officer Spencer Go</a> <a title="EMJ Rheumatology 6.1 2019 page 7" href="http://viewer.zmags.com/publication/ad75fc2f?page=7"> Welcome It is with great pleasure that I once aga</a> <a title="EMJ Rheumatology 6.1 2019 page 8" href="http://viewer.zmags.com/publication/ad75fc2f?page=8"> Simple. Fast. Precise. ELEVATING RHEUMATOLOGY GE</a> <a title="EMJ Rheumatology 6.1 2019 page 9" href="http://viewer.zmags.com/publication/ad75fc2f?page=9"> Foreword Dear colleagues, It is with great pleasu</a> <a title="EMJ Rheumatology 6.1 2019 page 10" href="http://viewer.zmags.com/publication/ad75fc2f?page=10"> </a> <a title="EMJ Rheumatology 6.1 2019 page 11" href="http://viewer.zmags.com/publication/ad75fc2f?page=11"> Congress Review Review of the European League </a> <a title="EMJ Rheumatology 6.1 2019 page 12" href="http://viewer.zmags.com/publication/ad75fc2f?page=12"> congress in order to help each achieve the very b</a> <a title="EMJ Rheumatology 6.1 2019 page 13" href="http://viewer.zmags.com/publication/ad75fc2f?page=13"> "In his opening ceremony discussion, Prof Bi</a> <a title="EMJ Rheumatology 6.1 2019 page 14" href="http://viewer.zmags.com/publication/ad75fc2f?page=14"> Rheumatoid Arthritis Could be Treated with Elect</a> <a title="EMJ Rheumatology 6.1 2019 page 15" href="http://viewer.zmags.com/publication/ad75fc2f?page=15"> Cyprus Sees Creation of a Rheumatology Nur</a> <a title="EMJ Rheumatology 6.1 2019 page 16" href="http://viewer.zmags.com/publication/ad75fc2f?page=16"> Risk of Rheumatoid Arthritis Increased </a> <a title="EMJ Rheumatology 6.1 2019 page 17" href="http://viewer.zmags.com/publication/ad75fc2f?page=17"> Room for Improvement in Rheumatoid </a> <a title="EMJ Rheumatology 6.1 2019 page 18" href="http://viewer.zmags.com/publication/ad75fc2f?page=18"> Encouraging Results from Tildrakizumab </a> <a title="EMJ Rheumatology 6.1 2019 page 19" href="http://viewer.zmags.com/publication/ad75fc2f?page=19"> Pain Causing Suicidal Ideation in 10% </a> <a title="EMJ Rheumatology 6.1 2019 page 20" href="http://viewer.zmags.com/publication/ad75fc2f?page=20"> Time2Work Launched to Help the Unemployed </a> <a title="EMJ Rheumatology 6.1 2019 page 21" href="http://viewer.zmags.com/publication/ad75fc2f?page=21"> Post-Denosumab Discontinuation Bone Mineral Den</a> <a title="EMJ Rheumatology 6.1 2019 page 22" href="http://viewer.zmags.com/publication/ad75fc2f?page=22"> Psoriatic Arthritis Severity Linked to </a> <a title="EMJ Rheumatology 6.1 2019 page 23" href="http://viewer.zmags.com/publication/ad75fc2f?page=23"> Pain and Function in Hand Osteoarthritis Improved</a> <a title="EMJ Rheumatology 6.1 2019 page 24" href="http://viewer.zmags.com/publication/ad75fc2f?page=24"> CLINICAL DIAGNOSTICS Therapeutic Dr</a> <a title="EMJ Rheumatology 6.1 2019 page 25" href="http://viewer.zmags.com/publication/ad75fc2f?page=25"> Meet the Editorial Board T he</a> <a title="EMJ Rheumatology 6.1 2019 page 26" href="http://viewer.zmags.com/publication/ad75fc2f?page=26"> Q5 the leaders of major projects in rheumatology,</a> <a title="EMJ Rheumatology 6.1 2019 page 27" href="http://viewer.zmags.com/publication/ad75fc2f?page=27"> Dr Suzanne Verstappenen Reader in Musculoskeletal</a> <a title="EMJ Rheumatology 6.1 2019 page 28" href="http://viewer.zmags.com/publication/ad75fc2f?page=28"> Q5 consideration could be work, for another it mi</a> <a title="EMJ Rheumatology 6.1 2019 page 29" href="http://viewer.zmags.com/publication/ad75fc2f?page=29"> Meet the Organisers E ach year, the</a> <a title="EMJ Rheumatology 6.1 2019 page 30" href="http://viewer.zmags.com/publication/ad75fc2f?page=30"> Q5 With PRES celebrating "I </a> <a title="EMJ Rheumatology 6.1 2019 page 31" href="http://viewer.zmags.com/publication/ad75fc2f?page=31"> Dieter Wiek en EULAR Vice President representing </a> <a title="EMJ Rheumatology 6.1 2019 page 32" href="http://viewer.zmags.com/publication/ad75fc2f?page=32"> Q6 Is there a session that you are particular</a> <a title="EMJ Rheumatology 6.1 2019 page 33" href="http://viewer.zmags.com/publication/ad75fc2f?page=33"> Optimising Patient Management in Rheumatoid Art</a> <a title="EMJ Rheumatology 6.1 2019 page 34" href="http://viewer.zmags.com/publication/ad75fc2f?page=34"> Introduction Anti-TNF biologics have revolutionis</a> <a title="EMJ Rheumatology 6.1 2019 page 35" href="http://viewer.zmags.com/publication/ad75fc2f?page=35"> Clinical considerations • Length of time with </a> <a title="EMJ Rheumatology 6.1 2019 page 36" href="http://viewer.zmags.com/publication/ad75fc2f?page=36"> stored all biological DMARD (bDMARD) packages wit</a> <a title="EMJ Rheumatology 6.1 2019 page 37" href="http://viewer.zmags.com/publication/ad75fc2f?page=37"> a biosimilar, a therapy will have demonstrated eq</a> <a title="EMJ Rheumatology 6.1 2019 page 38" href="http://viewer.zmags.com/publication/ad75fc2f?page=38"> The Therapeutic Window of Opportunity: Halting D</a> <a title="EMJ Rheumatology 6.1 2019 page 39" href="http://viewer.zmags.com/publication/ad75fc2f?page=39"> TDM may be helpful in facilitating cost-effective</a> <a title="EMJ Rheumatology 6.1 2019 page 40" href="http://viewer.zmags.com/publication/ad75fc2f?page=40"> rheumatology: Emerging concepts and their implica</a> <a title="EMJ Rheumatology 6.1 2019 page 41" href="http://viewer.zmags.com/publication/ad75fc2f?page=41"> Considering the Patient Perspective: Challenges F</a> <a title="EMJ Rheumatology 6.1 2019 page 42" href="http://viewer.zmags.com/publication/ad75fc2f?page=42"> for the management of PsA, minimal disease activi</a> <a title="EMJ Rheumatology 6.1 2019 page 43" href="http://viewer.zmags.com/publication/ad75fc2f?page=43"> Gender differences have also been observed in mal</a> <a title="EMJ Rheumatology 6.1 2019 page 44" href="http://viewer.zmags.com/publication/ad75fc2f?page=44"> Additionally, women with definite sacroiliitis may</a> <a title="EMJ Rheumatology 6.1 2019 page 45" href="http://viewer.zmags.com/publication/ad75fc2f?page=45"> how effectively antibodies are transferred across</a> <a title="EMJ Rheumatology 6.1 2019 page 46" href="http://viewer.zmags.com/publication/ad75fc2f?page=46"> Rheumatologists therefore need to see beyond clin</a> <a title="EMJ Rheumatology 6.1 2019 page 47" href="http://viewer.zmags.com/publication/ad75fc2f?page=47"> In contrast, anxiety, depression, or both, has be</a> <a title="EMJ Rheumatology 6.1 2019 page 48" href="http://viewer.zmags.com/publication/ad75fc2f?page=48"> potential of tumor necrosis 2</a> <a title="EMJ Rheumatology 6.1 2019 page 49" href="http://viewer.zmags.com/publication/ad75fc2f?page=49"> to consider for use of antirheumatic drugs before</a> <a title="EMJ Rheumatology 6.1 2019 page 50" href="http://viewer.zmags.com/publication/ad75fc2f?page=50"> Metacognition in Rheumatoid Arthritis: Thinking </a> <a title="EMJ Rheumatology 6.1 2019 page 51" href="http://viewer.zmags.com/publication/ad75fc2f?page=51"> of RA: how we define remission, how we measure rem</a> <a title="EMJ Rheumatology 6.1 2019 page 52" href="http://viewer.zmags.com/publication/ad75fc2f?page=52"> between physicians and patient, offers a way fo</a> <a title="EMJ Rheumatology 6.1 2019 page 53" href="http://viewer.zmags.com/publication/ad75fc2f?page=53"> Reasons for this include a lack of awareness amon</a> <a title="EMJ Rheumatology 6.1 2019 page 54" href="http://viewer.zmags.com/publication/ad75fc2f?page=54"> results.35-37 In the ARCTIC study, ultrasoun</a> <a title="EMJ Rheumatology 6.1 2019 page 55" href="http://viewer.zmags.com/publication/ad75fc2f?page=55"> MONARCH trial show that patients switched from ad</a> <a title="EMJ Rheumatology 6.1 2019 page 56" href="http://viewer.zmags.com/publication/ad75fc2f?page=56"> Following the failure of a TNFi, EULA</a> <a title="EMJ Rheumatology 6.1 2019 page 57" href="http://viewer.zmags.com/publication/ad75fc2f?page=57"> Diabetic patients Greater reduction in H</a> <a title="EMJ Rheumatology 6.1 2019 page 58" href="http://viewer.zmags.com/publication/ad75fc2f?page=58"> Interventionstoincreaseempathiccommunication have</a> <a title="EMJ Rheumatology 6.1 2019 page 59" href="http://viewer.zmags.com/publication/ad75fc2f?page=59"> current perspective. Rheumatol Int. 2016;36(5):68</a> <a title="EMJ Rheumatology 6.1 2019 page 60" href="http://viewer.zmags.com/publication/ad75fc2f?page=60"> a treat-to-target approach in 58</a> <a title="EMJ Rheumatology 6.1 2019 page 61" href="http://viewer.zmags.com/publication/ad75fc2f?page=61"> Fine-Tuning the Treatment of Psoriatic Arthritis:</a> <a title="EMJ Rheumatology 6.1 2019 page 62" href="http://viewer.zmags.com/publication/ad75fc2f?page=62"> rationale for targeting the IL-12/23 pathway. He </a> <a title="EMJ Rheumatology 6.1 2019 page 63" href="http://viewer.zmags.com/publication/ad75fc2f?page=63"> Spondylitis Enthesitis Score (MASES) at 24 w</a> <a title="EMJ Rheumatology 6.1 2019 page 64" href="http://viewer.zmags.com/publication/ad75fc2f?page=64"> Focus on the IL-23 Pathway Professor Georg Schett</a> <a title="EMJ Rheumatology 6.1 2019 page 65" href="http://viewer.zmags.com/publication/ad75fc2f?page=65"> of Rheumatology criteria (ACR20) at Week 24,</a> <a title="EMJ Rheumatology 6.1 2019 page 66" href="http://viewer.zmags.com/publication/ad75fc2f?page=66"> Retained efficacy, even after switching from</a> <a title="EMJ Rheumatology 6.1 2019 page 67" href="http://viewer.zmags.com/publication/ad75fc2f?page=67"> significantly higher PASI 90 and 100 rates than fo</a> <a title="EMJ Rheumatology 6.1 2019 page 68" href="http://viewer.zmags.com/publication/ad75fc2f?page=68"> Panel Discussion and Concluding Remarks The facul</a> <a title="EMJ Rheumatology 6.1 2019 page 69" href="http://viewer.zmags.com/publication/ad75fc2f?page=69"> References 1. Siebert S et al. Why did IL-23</a> <a title="EMJ Rheumatology 6.1 2019 page 70" href="http://viewer.zmags.com/publication/ad75fc2f?page=70"> phosphodiesterase 4 inhibitor. Ann Rheum Dis. 201</a> <a title="EMJ Rheumatology 6.1 2019 page 71" href="http://viewer.zmags.com/publication/ad75fc2f?page=71"> Abstract Reviews Our congress team have handpic</a> <a title="EMJ Rheumatology 6.1 2019 page 72" href="http://viewer.zmags.com/publication/ad75fc2f?page=72"> UCB, Eisai, Chugai, Ono, Gilead; and received spe</a> <a title="EMJ Rheumatology 6.1 2019 page 73" href="http://viewer.zmags.com/publication/ad75fc2f?page=73"> During the 24-week double-blind period, 190 </a> <a title="EMJ Rheumatology 6.1 2019 page 74" href="http://viewer.zmags.com/publication/ad75fc2f?page=74"> Acknowledgements: This work has been supported by</a> <a title="EMJ Rheumatology 6.1 2019 page 75" href="http://viewer.zmags.com/publication/ad75fc2f?page=75"> total number of patients still on the treatment a</a> <a title="EMJ Rheumatology 6.1 2019 page 76" href="http://viewer.zmags.com/publication/ad75fc2f?page=76"> Keywords: Preclinical phases, rheumatoid arthriti</a> <a title="EMJ Rheumatology 6.1 2019 page 77" href="http://viewer.zmags.com/publication/ad75fc2f?page=77"> METHODS Next-generation sequencing of the </a> <a title="EMJ Rheumatology 6.1 2019 page 78" href="http://viewer.zmags.com/publication/ad75fc2f?page=78"> Comparison of PAXgene and Tempus Whole Blood </a> <a title="EMJ Rheumatology 6.1 2019 page 79" href="http://viewer.zmags.com/publication/ad75fc2f?page=79"> can use either tubes for IFN score determination </a> <a title="EMJ Rheumatology 6.1 2019 page 80" href="http://viewer.zmags.com/publication/ad75fc2f?page=80"> Immunogenicity constitutes an important </a> <a title="EMJ Rheumatology 6.1 2019 page 81" href="http://viewer.zmags.com/publication/ad75fc2f?page=81"> Immunometabolism in Rheumatic Disease: The Role </a> <a title="EMJ Rheumatology 6.1 2019 page 82" href="http://viewer.zmags.com/publication/ad75fc2f?page=82"> the pathogenesis of systemic lupus erythematosus,</a> <a title="EMJ Rheumatology 6.1 2019 page 83" href="http://viewer.zmags.com/publication/ad75fc2f?page=83"> This has resulted in further research investigati</a> <a title="EMJ Rheumatology 6.1 2019 page 84" href="http://viewer.zmags.com/publication/ad75fc2f?page=84"> osteoarthritis (OA). OA chondrocytes stimulated b</a> <a title="EMJ Rheumatology 6.1 2019 page 85" href="http://viewer.zmags.com/publication/ad75fc2f?page=85"> Mitochondrial oxygen consumption was also not</a> <a title="EMJ Rheumatology 6.1 2019 page 86" href="http://viewer.zmags.com/publication/ad75fc2f?page=86"> associated with driving further dyslipidaemia</a> <a title="EMJ Rheumatology 6.1 2019 page 87" href="http://viewer.zmags.com/publication/ad75fc2f?page=87"> kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in </a> <a title="EMJ Rheumatology 6.1 2019 page 88" href="http://viewer.zmags.com/publication/ad75fc2f?page=88"> to immunometabolism for immunologists. Nat Rev Im</a> <a title="EMJ Rheumatology 6.1 2019 page 89" href="http://viewer.zmags.com/publication/ad75fc2f?page=89"> 2005;32(12):2311-6. 49. Toms TE et al. Dyslipida</a> <a title="EMJ Rheumatology 6.1 2019 page 90" href="http://viewer.zmags.com/publication/ad75fc2f?page=90"> Postmenopausal Osteoporosis: A Mini Review Auth</a> <a title="EMJ Rheumatology 6.1 2019 page 91" href="http://viewer.zmags.com/publication/ad75fc2f?page=91"> including bisphosphonates, denosumab, oestroge</a> <a title="EMJ Rheumatology 6.1 2019 page 92" href="http://viewer.zmags.com/publication/ad75fc2f?page=92"> Oestrogen Mesenchymal stem cell </a> <a title="EMJ Rheumatology 6.1 2019 page 93" href="http://viewer.zmags.com/publication/ad75fc2f?page=93"> Bone morphogenetic proteins (BMP), TGF-β, ins</a> <a title="EMJ Rheumatology 6.1 2019 page 94" href="http://viewer.zmags.com/publication/ad75fc2f?page=94"> Traditional Diagnostic Regimen BMD-derived, nor</a> <a title="EMJ Rheumatology 6.1 2019 page 95" href="http://viewer.zmags.com/publication/ad75fc2f?page=95"> However, the limitations of these biomarkers</a> <a title="EMJ Rheumatology 6.1 2019 page 96" href="http://viewer.zmags.com/publication/ad75fc2f?page=96"> respectively.1 However, it has been reported to c</a> <a title="EMJ Rheumatology 6.1 2019 page 97" href="http://viewer.zmags.com/publication/ad75fc2f?page=97"> Table 1 continued. Total </a> <a title="EMJ Rheumatology 6.1 2019 page 98" href="http://viewer.zmags.com/publication/ad75fc2f?page=98"> dynamics of BMD and bone turnover markers contr</a> <a title="EMJ Rheumatology 6.1 2019 page 99" href="http://viewer.zmags.com/publication/ad75fc2f?page=99"> estrogen receptor expression in human osteoblasts</a> <a title="EMJ Rheumatology 6.1 2019 page 100" href="http://viewer.zmags.com/publication/ad75fc2f?page=100"> 54. de Villiers TJ, Stevenson JC. The WHI: </a> <a title="EMJ Rheumatology 6.1 2019 page 101" href="http://viewer.zmags.com/publication/ad75fc2f?page=101"> Update on the Diagnosis and Anticoagulant Treatm</a> <a title="EMJ Rheumatology 6.1 2019 page 102" href="http://viewer.zmags.com/publication/ad75fc2f?page=102"> EPIDEMIOLOGY Although aPL are reported in 1–5% of</a> <a title="EMJ Rheumatology 6.1 2019 page 103" href="http://viewer.zmags.com/publication/ad75fc2f?page=103"> During the evolution of APS, a number of u</a> <a title="EMJ Rheumatology 6.1 2019 page 104" href="http://viewer.zmags.com/publication/ad75fc2f?page=104"> and one laboratory criterion (LAC, aCL, or </a> <a title="EMJ Rheumatology 6.1 2019 page 105" href="http://viewer.zmags.com/publication/ad75fc2f?page=105"> The second test should be a sensitive activated t</a> <a title="EMJ Rheumatology 6.1 2019 page 106" href="http://viewer.zmags.com/publication/ad75fc2f?page=106"> young patients with provoked VTE, recurrent spont</a> <a title="EMJ Rheumatology 6.1 2019 page 107" href="http://viewer.zmags.com/publication/ad75fc2f?page=107"> Table 2: Randomised controlled trials evaluating </a> <a title="EMJ Rheumatology 6.1 2019 page 108" href="http://viewer.zmags.com/publication/ad75fc2f?page=108"> Table 2 continued. Study Number of patients Patie</a> <a title="EMJ Rheumatology 6.1 2019 page 109" href="http://viewer.zmags.com/publication/ad75fc2f?page=109"> were enrolled in the RCT evaluating the VKA.47,48</a> <a title="EMJ Rheumatology 6.1 2019 page 110" href="http://viewer.zmags.com/publication/ad75fc2f?page=110"> diagnosis of APS needs the simultaneous</a> <a title="EMJ Rheumatology 6.1 2019 page 111" href="http://viewer.zmags.com/publication/ad75fc2f?page=111"> 37. Andreoli L et al. Clinical character</a> <a title="EMJ Rheumatology 6.1 2019 page 112" href="http://viewer.zmags.com/publication/ad75fc2f?page=112"> Secukinumab in the Management of Psoriatic </a> <a title="EMJ Rheumatology 6.1 2019 page 113" href="http://viewer.zmags.com/publication/ad75fc2f?page=113"> PSORIATIC ARTHRITIS IL-17 IN THE PATHOGENESIS OF</a> <a title="EMJ Rheumatology 6.1 2019 page 114" href="http://viewer.zmags.com/publication/ad75fc2f?page=114"> Table 1: Efficacy of secukinumab on the basis of </a> <a title="EMJ Rheumatology 6.1 2019 page 115" href="http://viewer.zmags.com/publication/ad75fc2f?page=115"> Patients of the placebo group were re-randomised </a> <a title="EMJ Rheumatology 6.1 2019 page 116" href="http://viewer.zmags.com/publication/ad75fc2f?page=116"> Table 2: Efficacy of secukinumab in the resolutio</a> <a title="EMJ Rheumatology 6.1 2019 page 117" href="http://viewer.zmags.com/publication/ad75fc2f?page=117"> Table 3: Efficacy of secukinumab in the resolutio</a> <a title="EMJ Rheumatology 6.1 2019 page 118" href="http://viewer.zmags.com/publication/ad75fc2f?page=118"> PROGRESSION EFFECT ON RADIOGRAPHIC Retardation </a> <a title="EMJ Rheumatology 6.1 2019 page 119" href="http://viewer.zmags.com/publication/ad75fc2f?page=119"> and 58.4% of patients in the placebo group).10 Mo</a> <a title="EMJ Rheumatology 6.1 2019 page 120" href="http://viewer.zmags.com/publication/ad75fc2f?page=120"> year data of secukinumab has also shown sus</a> <a title="EMJ Rheumatology 6.1 2019 page 121" href="http://viewer.zmags.com/publication/ad75fc2f?page=121"> 30. DeSelm CJ et al. IL-17 mediates estr</a> <a title="EMJ Rheumatology 6.1 2019 page 122" href="http://viewer.zmags.com/publication/ad75fc2f?page=122"> A Review of Adalimumab Biosimilars for the Trea</a> <a title="EMJ Rheumatology 6.1 2019 page 123" href="http://viewer.zmags.com/publication/ad75fc2f?page=123"> INTRODUCTION Adalimumab is a recombinant full</a> <a title="EMJ Rheumatology 6.1 2019 page 124" href="http://viewer.zmags.com/publication/ad75fc2f?page=124"> Adalimumab biosimilar candidates were tested agai</a> <a title="EMJ Rheumatology 6.1 2019 page 125" href="http://viewer.zmags.com/publication/ad75fc2f?page=125"> not considered by the regulatory agencies to comp</a> <a title="EMJ Rheumatology 6.1 2019 page 126" href="http://viewer.zmags.com/publication/ad75fc2f?page=126"> Table 2 continued. Biosimilar Trial phase </a> <a title="EMJ Rheumatology 6.1 2019 page 127" href="http://viewer.zmags.com/publication/ad75fc2f?page=127"> Table 3: Phase III clinical trials for each appro</a> <a title="EMJ Rheumatology 6.1 2019 page 128" href="http://viewer.zmags.com/publication/ad75fc2f?page=128"> Table 3 continued. Biosimilar Trial phase </a> <a title="EMJ Rheumatology 6.1 2019 page 129" href="http://viewer.zmags.com/publication/ad75fc2f?page=129"> Table 3 continued. Biosimilar Trial phase </a> <a title="EMJ Rheumatology 6.1 2019 page 130" href="http://viewer.zmags.com/publication/ad75fc2f?page=130"> MSB11022 performed similarly to reference drug in</a> <a title="EMJ Rheumatology 6.1 2019 page 131" href="http://viewer.zmags.com/publication/ad75fc2f?page=131"> of adalimumab indicate that switching resulted in</a> <a title="EMJ Rheumatology 6.1 2019 page 132" href="http://viewer.zmags.com/publication/ad75fc2f?page=132"> growing market share of 10%, 35%, 60%, and 90%, s</a> <a title="EMJ Rheumatology 6.1 2019 page 133" href="http://viewer.zmags.com/publication/ad75fc2f?page=133"> 501 and adalimumab. Ann Rheum Dis. 2017;76(3):526</a> <a title="EMJ Rheumatology 6.1 2019 page 134" href="http://viewer.zmags.com/publication/ad75fc2f?page=134"> Real-World Experience of Apremilast in Treating </a> <a title="EMJ Rheumatology 6.1 2019 page 135" href="http://viewer.zmags.com/publication/ad75fc2f?page=135"> PsA.3-6 There is, however, limited real-world dat</a> <a title="EMJ Rheumatology 6.1 2019 page 136" href="http://viewer.zmags.com/publication/ad75fc2f?page=136"> (Figure 2). The reduction in joint counts at Week</a> <a title="EMJ Rheumatology 6.1 2019 page 137" href="http://viewer.zmags.com/publication/ad75fc2f?page=137"> Week 0 Week 16 Week 52 </a> <a title="EMJ Rheumatology 6.1 2019 page 138" href="http://viewer.zmags.com/publication/ad75fc2f?page=138"> Week 0 Week 16 </a> <a title="EMJ Rheumatology 6.1 2019 page 139" href="http://viewer.zmags.com/publication/ad75fc2f?page=139"> will inform the authors as to any benefits of thes</a> <a title="EMJ Rheumatology 6.1 2019 page 140" href="http://viewer.zmags.com/publication/ad75fc2f?page=140"> </a>